摘要
在正常的细胞生理学,线粒体起着至关重要的作用,最近几年发现它们与众多疾病的发生有关。这两个角色的核心是在两种不同形态之间互换的能力:一个细长的相互链接型和支离破碎的离散表型——变化的过程分别是收线粒体融合与分裂蛋白的调控。在这篇综述中,我们专注于线粒体融合蛋白视神经萎缩蛋白1(OPA1)在心血管健康和疾病中的作用,我们探索其作为一个潜在治疗心血管和代谢疾病的目标。
关键词: 心血管疾病,裂变,融合,线粒体形态学,视神经萎缩蛋白1
Current Drug Targets
Title:OPA1 in Cardiovascular Health and Disease
Volume: 16 Issue: 8
Author(s): Niall Burke, Andrew R. Hall and Derek J. Hausenloy
Affiliation:
关键词: 心血管疾病,裂变,融合,线粒体形态学,视神经萎缩蛋白1
摘要: Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
Export Options
About this article
Cite this article as:
Niall Burke, Andrew R. Hall and Derek J. Hausenloy , OPA1 in Cardiovascular Health and Disease, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150102113648
DOI https://dx.doi.org/10.2174/1389450116666150102113648 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance
Current Cardiology Reviews Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Utility of the Electrocardiogram in Drug Overdose and Poisoning: Theoretical Considerations and Clinical Implications
Current Cardiology Reviews Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Cell Death and Survival Through the Endoplasmic Reticulum- Mitochondrial Axis
Current Molecular Medicine Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design Clozapine Safety, 40 Years Later
Current Drug Safety Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Role of Methylglyoxal in Diabetic Cardiovascular and Kidney Diseases: Insights from Basic Science for Application into Clinical Practice
Current Pharmaceutical Design Augmentation of Creatine in the Heart
Mini-Reviews in Medicinal Chemistry Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets